You are being asked to take part in a clinical research study called XL092-303 because you have already received standard treatment for your cancer and your cancer has worsened or become intolerant to standard treatment for your type of cancer. If you join this study, you will receive investigational drugs called XL092 plus atezolizumab, or regorafenib. An investigational drug is a drug that has not been approved by any regulatory agency like the United States Food and Drug Administration (FDA) to treat people for the use described in this study.